August 23, 2016 скачать в хорошем качестве

August 23, 2016

My video on once-a-month injection of Repatha, a PCSK9 inhibitor that gets your LDL to goal! I consider PCKS9 Inhibitor class highly important, a revolution in cardiology and treatment of LDL Cholesterol with the potential to eliminate heart attacks and strokes! Please share. In the US, Crestor is the fourth top drug by sales at $5,502,148,010 annually (according to IMS National Prescription Audit, IMS Health) and Lipitor was at Lipitor $7.2 billion. Cholesterol-lowering Statin drugs have been shown to be life-saving in numerous studies in high-risk patients (those with multiple risk factors such as age, diabetes, family history, smoking, hypertension, and hyperlipidemia...) as well as in primary prevention. In patients who have had heart attacks or stroke or are diabetic, it is a must to have LDL (bad cholesterol) lowered to under 70, although I try for even lower- below 50! Doctors must be very cautious when using these drugs and watch out for potential harmful effects. These include muscle damage and liver injury etc. Sometimes, the symptoms are obvious with severe pain. But often there is mild aches confused with arthritic pain and fatigue. I check CPK, LFTs and here you see mild elevation in CK-MB and Myoglobin (see typically in Statin muscle injury.) Some doctors check blood levels only once a year. I do it at least three times a year and actively look for Statin injury. If you are a patient on Statin (Lipitor, Crestor, Mevacor, Simvastatin, etc...) ask for your levels to be checked. There are now other options which are much more effective and less harmful if you qualify. Reflecting shorter-term results in a prior trial, the phase 3 Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 (GAUSS-3) trial "met its co–primary end points," Amgen said in a statement aimed at the investment community[1]. It means that one of its highest-profile products, ‪#‎evolocumab‬ (‪#‎Repatha‬), already on the market, cut mean LDL-C levels significantly further than treatment with ezetimibe over 24 weeks in patients who had been intolerant of statin therapy due to "muscle-related side effects," which usually means pain or spasms. "There were no new safety findings," the company said. As is customary in such announcements, relative outcomes implying a significant difference were provided without specific numbers. GAUSS-3, randomized and with double-blinding, is reported to have enrolled 519 patients. Evolocumab, a human monoclonal antibody for proprotein convertase subtilisin-kexin type 9 (PCSK9), lowers LDL-C via an entirely different mechanism compared with statins or ezetimibe. The approvals of evolocumab and a competing PCSK9 inhibitor alirocumab (‪#‎Praluent‬, ‪#‎Sanofi‬/Regeneron) indicated them for LDL-C lowering in conjunction with maximally tolerated statins. Approval in the statin-intolerant population tested in GAUSS-2 and GAUSS-3 would expand the indication to a modestly broader population. Amgen is sponsoring a large cardiovascular-outcomes trial it hopes will settle the big PCSK9-inhibitor question in the medical community, whether the LDL-C-lowering shown by these drugs—evolocumab in this case—can translate to fewer CV events. Top-line results from such a trial, called FOURIER, which randomized about 27,500 patients with clinical cardiovascular disease, "are anticipated in the second half of 2016," according to the company.